România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing deutschland gmbh - germania - venlafaxinum - caps. elib. prel. - 37,5 mg - antidepresive alte antidepresive

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing deutschland gmbh - germania - venlafaxinum - caps. elib. prel. - 75 mg - antidepresive alte antidepresive

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc ortomed srl -

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sc aktivort srl -

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

actavis hf. - islanda - topiramatum - compr. film. - 100mg - antiepileptice alte antiepileptice

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

apl swift services (malta) limited - malta - naproxenum - compr. - 250mg - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic

Uniunea Europeană - română - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porci - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Uniunea Europeană - română - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunologii pentru suidae - porci (pentru îngrășare) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Uniunea Europeană - română - EMA (European Medicines Agency)

molmed spa - alogen t celule modificate genetic cu un vector retrovirale codificarea pentru o formă trunchiată a receptorilor de factor de creştere nervos uman afinitate scăzută (Δlngfr) si herpes simplex virus timidin chinază (hsv tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - agenți antineoplazici - zalmoxis este indicat ca tratament adjuvant în transplantul de celule stem hematopoietice haploidentic (hsct) de pacienţi adulţi cu tumori maligne hematologice cu risc ridicat.